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The eﬀectiveness of extending treatment duration as response guided therapy was previously reported 
for chronic hepatitis C (CHC) genotype 1,  but is still controversial for genotype 2.  The present study 
is a retrospective cohort study to investigate the eﬀectiveness of extending treatment duration in ther-
apy with pegylated interferon and ribavirin for patients with CHC genotype 2 by focusing on the tim-
ing at which patients obtained undetectable HCV RNA.  A total of 306 patients who obtained undetect-
able HCV RNA by week 24 of treatment and completed 24 weeks of treatment were enrolled.  Rapid 
virological response (RVR) to standard therapy was achieved by 122 patients (51ｵ),  and 89ｵ of them 
obtained sustained virological response (SVR),  while 69ｵ of non-RVR patients achieved SVR.  Non-
RVR patients with undetectable HCV RNA at week 8,  and insuﬃcient adherence＜80ｵ pegylated 
interferon and ribavirin during the ﬁrst 24 weeks,  signiﬁcantly improved their SVR rate by extended 
therapy.  Among patients receiving extended therapy,  drug adherences did not diﬀer between SVR and 
non-SVR patients,  indicating that extending treatment duration might compensate for insuﬃcient 
antiviral eﬀects due to insuﬃcient drug adherences.  This ﬁnding might be useful in creating a guide-
line for extending treatment duration for patients with CHC genotype 2.
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epatitis C virus (HCV) infection is the pre-
dominant cause of liver cirrhosis and hepatocel-
lular carcinoma (HCC) in many countries,  including 
Japan,  the United States,  and European countries 
[1,  2].  Once HCV infection becomes chronic,  it is 
rarely resolved without antiviral treatment.  Occasionally,  
chronic hepatitis C (CHC) progresses to liver cirrho-
sis and HCC after as long a period as 30 years with-
out any disease-related symptoms.
　 Despite foreseeable approval of interferon (IFN)-
free regimens for patients with CHC genotype 2 in 
H
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Japan [3],  the combination of pegylated interferon 
(PegIFN) and ribavirin (RBV) will likely remain the 
treatment of choice in patients who cannot obtain 
sustained virological response (SVR) to antiviral 
treatment with IFN-free regimens.
　 IFN therapy is eﬀective at eliminating the virus and 
reducing the risk of HCC developing in CHC patients 
[4].  The standard treatment duration for treatment 
with PegIFN and RBV in patients with CHC genotype 
2 is 24 weeks.  Recent advances in antiviral therapy 
for patients with CHC genotype 1 revealed the eﬀec-
tiveness of extending treatment duration in slow viro-
logical responders [5-8],  and similar improvement is 
supposed in anti-HCV therapy for patients with CHC 
genotype 2; however,  the indications for extending 
treatment duration are still unresolved [9-12].
　 The present study retrospectively studied the fac-
tors associated with virological response during stan-
dard antiviral therapy with PegIFN and RBV in 
patients with CHC genotype 2,  and assessed the 
additional beneﬁt of extending treatment duration,  in 
order to develop a guideline for extending treatment 
duration.
Methods
　 Patients. The present study enrolled consecu-
tive patients with CHC genotype 2,  who had under-
gone combination therapy with PegIFN and RBV at 
the Okayama University Hospital or its aﬃliated hos-
pitals between 2005 and 2011,  and who obtained 
undetectable HCV RNA by week 24 of treatment and 
completed 24 weeks of treatment.  Patients co-infected 
with hepatitis B virus or human immunodeﬁciency 
virus and patients with complicating autoimmune liver 
diseases were excluded from the study.  HCC was 
ruled out by means of dynamic computed tomography 
or magnetic resonance imaging before the therapy.  
The study was performed in accordance with the 
Helsinki declaration,  and all the protocols were 
approved by the ethics committees of the institutes.  
All patients provided informed consent before enroll-
ing in the study.  The study was registered for univer-
sity hospital medical information network-clinical tri-
als registry (UMIN 000001031).
　 Virological response. All patients had HCV 
RNA＞5 log IU/mL in their sera,  as conﬁrmed by the 
TaqMan HCV assay (Roche Molecular Diagnostics,  
Tokyo,  Japan) or the COBAS AMPLICOR HCV test 
Ver. 2 (Roche Molecular Diagnostics).  Their viral 
statuses were monitored during the treatment by the 
TaqMan HCV assay or the qualitative COBAS 
AMPLICOR HCV test Ver. 2.  Rapid virological 
response (RVR) was deﬁned as undetectable HCV 
RNA in the serum at week 4 of treatment according to 
the guidelines for the management of hepatitis C virus 
infection from Japan Society of Hepatology [13].  A 
virological response with detectable HCV RNA at 
week 4 of treatment and undetectable HCV RNA at 
week 8 of treatment was deﬁned as non-RVR-A.  Slow 
virological response with detectable HCV RNA at 
week 8 of treatment and undetectable HCV RNA at 
the end of treatment was deﬁned as non-RVR-B.  
Sustained virological response (SVR) was deﬁned as 
undetectable HCV RNA in the serum 24 weeks after 
the completion of treatment [13].
　 IFN therapy. The patients received a combina-
tion of PegIFN-alpha 2b (1.5µg/kg of body weight) by 
subcutaneous injection every week with RBV (600-
1,000mg daily,  according to body weight).  The doses 
of PegIFN and RBV were individually reduced during 
the treatment whenever needed to lessen adverse 
eﬀects,  and these dose reductions were performed 
according to the labeling.  As the so-called extended 
therapy,  the treatment duration was extended from 24 
weeks to 28-48 weeks in some of those patients who 
had undergone IFN therapy previously,  or treatment-
naïve patients without RVR.
　 Statistical analysis. Data are expressed as 
means±standard deviations.  The rates of patients 
attaining SVR were compared between groups with the 
Chi-square test or the Fisher exact probability test.  
Factors or patient characteristics associated with 
virological responses were analyzed by logistic regres-
sion,  and signiﬁcant factors in univariate analysis 
were selected in a stepwise manner for the multivari-
ate analysis.  A cut-oﬀ value was deﬁned a priori for 
each parameter: the lower limit of the normal range 
for white blood cells,  hemoglobin,  platelet count,  and 
creatinine,  and the upper limit of the normal range for 
alanine aminotransferase and γ-glutamyl transpepti-
dase.  The Wilcoxon rank sum test was used to com-
pare drug adherence between SVR and non-SVR 
patients.  P values＜0.05 were considered signiﬁcant.  
The statistical analyses were performed using JMP 
software Ver. 11 (SAS Institute,  Cary,  NC,  USA).
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Results
　 Characteristics of patients enrolled in the 
study. Details of patient disposition and ﬂow 
through the study are shown in Fig.  1.  Of the 306 
patients enrolled in the study,  140 patients obtained 
RVR,  while 166 patients did not.  Among those with 
non-RVR,  serum HCV RNA became undetectable by 
week 8 of treatment in 115 patients (non-RVR-A 
group),  and 51 patients showed undetectable HCV 
RNA sometime between weeks 8 and 24 (non-RVR-B 
group).
　 The characteristics of patients enrolled in the 
study are shown in Table 1.  The mean age was 54 
years,  and 151 patients (49ｵ) were female.  A total 
of 239 patients received the standard 24-week ther-
apy,  while 67 patients,  including 21 IFN-naïve patients,  
were treated with the extended therapy.  Elderly 
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Table 1　 Patient characteristics
Factors All(n＝306)
Standard
(n＝239)
Extended
(n＝67) P
Gender (male/female) 155/151 131/108 24/43 0.0060
Age (years) 54±13 53±13 58±12 0.0029
Body weight (kg) 62±11 62±11 60±12 0.18
Previous interferon (yes/no) 125/181 79/160 46/21 ＜0.0001
ALT (IU/L) 79±83 82±88 69±58 0.71
γGT (IU/L) 63±88 67±96 50±47 0.48
White blood cell count (/µL) 5,184±1,516 5,269±1,459 4,881±1,680 0.024
Hemoglobin (g/dL) 14±1.6 14±1.6 14±1.4 0.016
Platelet count (10,000/µL) 18±5.7 18±5.4 17±6.6 0.0016
Creatinine (IU/L) 0.72±0.15 0.72±0.14 0.71±0.18 0.55
Therapeutic outcomes (SVR/Relapse) 239/67 190/49 49/18 0.27
ALT,  alanine aminotransferase; γGT,  γ-glutamyl transpeptidase; SVR,  sustained virological response.
Enrollment
N = 306
Standard therapy
N = 122
Extended therapy
N = 18
RVR
N = 140
non-RVR
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Standard therapy
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Fig. 1　 Patient treatment ﬂow diagram.  The treatment duration was extended in IFN-experienced patients or treatment-naïve patients 
without RVR.
female patients with previous IFN therapy received 
the extended therapy rather than the standard therapy,  
and showed lower counts of white blood cells and 
platelet and lower hemoglobin levels,  reﬂecting more 
advanced liver diseases than those receiving the stan-
dard therapy.  Among the 239 patients receiving the 
standard therapy,  190 patients (79ｵ) achieved SVR,  
and 49 patients suﬀered relapses,  while 49 patients 
(73ｵ) achieved SVR with extended therapy,  which 
did not show signiﬁcant statistical diﬀerence (p＝0.27,  
the Chi-square test).
　 Stepwise logistic regression analysis was done for 
all 306 patients enrolled in the study,  to clarify the 
pre-treatment patient characteristics that were associ-
ated with virological response.  Advanced age was 
signiﬁcantly associated with detectable HCV RNA at 
week 4 of treatment (p＝0.0051,  Table 2),  but no 
signiﬁcant factors associated with detectable HCV 
RNA at week 8 of treatment were found (Table 3).  
These results indicated that the patients of advanced 
age have slow virological response during the treat-
ment,  and may obtain therapeutic beneﬁts by receiving 
extended therapy.
　 Comparison of virological response between 
standard and extended therapy. We supposed 
that extending the treatment duration might improve 
therapeutic outcomes for slow virological responders,  
according to the theory of response-guided therapy,  
and assessed the associations of virological response 
during treatment with SVR.  In comparison of SVR 
rates by virological response during treatment,  shown 
in Fig.  2A,  122 patients (51ｵ) achieved RVR,  and of 
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Table 2　 Logistic regression analysis of the factors associated with detectable HCV RNA at week 4 of treatment
Univariate Multivariate
Factors Odds (range†) p Odds (range†) p
Gender (male＝1) 0.76 (0.49-1.2) 0.24
Age (years) 1.02 (1.0078-1.1) 0.0051 1.02 (1.0078-1.1) 0.0051
Body weight (kg) 0.98 (0.99-1.03) 0.14
Previous Interferon (yes＝1) 1.4 (0.88-2.2) 0.15
ALT (1: ＞42 IU/L) 1.5 (0.89-2.2) 0.15
γGT (1: ＞40 IU/L) 1.1 (0.64-1.6) 0.91
White blood cell count (1: ＞3,500/µL) 0.57 (0.26-1.2) 0.14
Hemoglobin (1: ＞13.5g/dL) 0.60 (0.37-0.94) 0.027
Platelet count (1: ＞150,000/µL) 0.69 (0.42-1.1) 0.13
Creatinine (1: ＞0.80 IU/L) 1.3 (0.78-2.2) 0.29
†95% conﬁdence interval; ALT,  alanine aminotransferase; γGT,  γ-glutamyl transpeptidase.
Table 3　 Logistic regression analysis of the factors associated with detectable HCV RNA at week 8 of treatment
Univariate
Factors Odds (range†) p
Gender (male＝1) 0.92 (0.50-1.7) 0.80
Age (years) 1.1 (0.99-1.1) 0.12
Body weight (kg) 0.99 (0.96-1.1) 0.38
Previous Interferon (yes＝1) 1.2 (0.66-2.3) 0.50
ALT (1: ＞42 IU/L) 1.3 (0.72-2.4) 0.37
γGT (1: ＞40 IU/L) 1.1 (0.57-1.9) 0.88
White blood cell count (1: ＞3,500/µL) 0.89 (0.37-2.5) 0.82
Hemoglobin (1: ＞13.5g/dL) 0.96 (0.53-1.8) 0.89
Platelet count (1: ＞150,000/µL) 0.77 (0.42-1.5) 0.43
Creatinine (1: ＞0.80 IU/L) 1.5 (0.76-3.3) 0.24
†95% conﬁdence interval; ALT,  alanine aminotransferase; γGT,  γ-glutamyl transpeptidase.
these,  109 (89ｵ) were identiﬁed as achieving SVR.  
The rates of SVR in the 2 types of non-RVR patients 
were 77ｵ (63/82) for non-RVR-A,  and 51ｵ (18/35) 
for non-RVR-B.  The rates of SVR patients with the 
standard therapy were signiﬁcantly higher in the 
patients with RVR than in the patients with non-RVR-
A and non-RVR-B (p＝0.016,  and p＜0.0001,  respec-
tively,  the Chi-square test).  A signiﬁcant diﬀerence 
in the SVR rate was also shown between patients with 
non-RVR-A and non-RVR-B (p＝0.0064).  On the other 
hand,  by extending the treatment duration,  the 
patients with non-RVR-A obtained a similar SVR rate 
to those with RVR (p＝1.0).  The extended-treatment 
patients with RVR or non-RVR-A still showed signiﬁ-
cantly higher SVR rates than those with non-RVR-B 
(p＝0.016,  and 0.010,  respectively).
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Fig. 2　 Associations of virological response and drug adherence with SVR.  A shows the rates of SVR with standard therapy and 
extended therapy for patient groups classiﬁed by diﬀerent virological responses during treatment.  B expresses the quintiles and medians of 
drug adherence to PegIFN and RBV regimens from 0 to 24 weeks of treatment in the standard and the extended therapy.
　 Analysis of drug adherence to PegIFN and 
RBV during the treatment with SVR. As for 
drug adherence to PegIFN and RBV during the 
24-week treatment,  most patients with low PegIFN 
adherence started the treatment with reduced PegIFN 
doses due to low platelet counts.  Dose reduction of 
PegIFN was rarely observed during the treatment.  
On the other hand,  patients with low RBV adherence 
showed dose reduction of RBV during the treatment 
because of progressive anemia.  As shown in Fig.  2B,  
drug adherences to PegIFN and RBV during the 
treatment with the standard therapy were signiﬁcantly 
higher in the patients achieving SVR than those 
resulting in non-SVR (p＜0.0001,  and p＜0.0001,  
respectively,  Wilcoxon rank sum test).  Interestingly,  
among the extended-therapy patients,  drug adherences 
to PegIFN and RBV did not diﬀer between the SVR 
and non-SVR patients.
　 Analysis of the eﬀectiveness of extending 
treatment duration. The eﬀectiveness of extend-
ing treatment duration was assessed by comparing the 
SVR rates between standard-therapy and extended-
therapy patients for each virological response group 
RVR,  non-RVR-A,  and non-RVR-B.  As shown in Fig.  
3,  there was no signiﬁcant improvement in the SVR 
rate for any virological response group by extending 
treatment duration (Fig.  3).  Further subgroup analy-
ses were done for the patients classiﬁed by virological 
response and drug adherence.  Among the patients 
with non-RVR-A and with insuﬃcient adherences of 
＜80ｵ to PegIFN and RBV,  the patients treated 
with the extended therapy obtained signiﬁcantly higher 
SVR rates than the patients receiving the standard 
therapy (p＝0.038,  and p＝0.023,  respectively,  the 
Chi-square test).  Such improvements were not observed 
among patients with RVR or non-RVR-B virological 
responses.
　 Analysis of the eﬀectiveness of extending 
treatment duration for patients with experience 
of antiviral therapy. Among 125 patients with 
prior experience of antiviral therapy,  64 patients had 
prior therapy with interferon or PegIFN,  and the 
other 61 had speciﬁc experience of the combination of 
PegIFN and RBV (Table 4).  Re-treatment with 
extended therapy showed 73ｵ SVR rates,  which was 
comparable to the SVR rate with re-treatment of the 
standard therapy (74ｵ).  Even when limited to the 64 
patients previously treated with the combination of 
PegIFN and RBV,  the SVR rates with the standard 
and extended therapy were similar,  and there was not 
statistically signiﬁcant diﬀerence (p＝1.0,  the Chi-
square test).
Discussion
　 The present study is a retrospective cohort study 
to investigate the eﬀectiveness of extending treatment 
duration for patients with CHC genotype 2,  and to 
clarify the factors associated with virological response 
during antiviral therapy.  The present study showed 
that patients with detectable HCV RNA at week 4 of 
treatment,  undetectable HCV RNA at week 8 of 
treatment,  and insuﬃcient drug adherence to PegIFN 
and RBV during treatment may improve therapeutic 
outcomes by extending treatment duration.  This 
assessment might be useful as a guideline for extend-
ing treatment duration.
　 Approximately half of the patients in the standard 
24-week therapy with PegIFN and RBV did not 
achieve RVR,  and only 69ｵ of these obtained SVR,  
while 89ｵ of the RVR patients achieved SVR,  which 
is consistent with ﬁndings of previous studies [9-12].  
The results in the present study showed no improve-
ment of the SVR rate by extending treatment duration 
for RVR patients.
　 It has been unclear whether non-RVR patients may 
beneﬁt from extending treatment duration [10].  
Yamaguchi et al.  reported that extending treatment 
duration could not signiﬁcantly improve therapeutic 
outcomes in non-RVR patients [11].  The N-CORE 
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Table 4　 Sustained virological response classiﬁed by previous therapy
Previous therapy Total (% SVR) Standard (% SVR) Extended (% SVR) P
Naïve 147/181 (81%) 132/160 (83%) 15/21 (71%) 0.24
Experienced 92/125 (74%) 58/79 (73%) 34/46 (74%) 1.0
PegIFN＋RBV 44/64 (69%) 24/35 (69%) 20/29 (69%) 1.0
SVR,  sustained virological response; PegIFN,  pegylated interferon; RBV,  ribavirin.
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Fig. 3　 Comparisons of SVR rates between therapies with standard and extended durations classiﬁed by virological response and drug 
adherence during the treatment.  The ﬁgures show the SVR rates with standard therapy (black bar) and extended therapy (open bar) in 
patient groups of RVR (A),  non-RVR-A (B),  and non-RVR-B (C).  The ﬁgures also show the SVR rates in patient groups with good (ｧ
80%) or insuﬃcient (＜80%) adherence to PegIFN and RBV.
trial showed a 10ｵ higher SVR rate by extending 
treatment duration,  but this result lacked statistical 
signiﬁcance [12].
　 We compared the SVR rates between the standard 
therapy and the extended therapy with more precise 
subgrouping by virological response; the non-RVR 
patients were classiﬁed in two groups: patients with 
detectable HCV RNA at week 4 of treatment and 
undetectable HCV RNA at week 8 of treatment (non-
RVR-A) and patients with detectable HCV RNA at 
week 8 of treatment and undetectable HCV RNA at 
the end of treatment (non-RVR-B).  The comparison of 
SVR rates and drug adherence during treatment 
among these groups revealed that the non-RVR-A 
patients who had insuﬃcient adherence to PegIFN or 
RBV obtained a signiﬁcantly higher SVR rate by 
extending treatment duration.
　 We also revealed that insuﬃcient drug adherence 
to the standard therapy,  but not to the extended 
therapy,  was associated with non-SVR,  which indi-
cated that extending treatment duration in these 
patients eﬀectively compensated for the insuﬃcient 
antiviral eﬀects of PegIFN or RBV due to insuﬃcient 
drug adherence.
　 In terms of slow responders who had detectable 
HCV RNA at week 8 of treatment (non-RVR-B),  they 
had a signiﬁcantly lower SVR rate than the patients 
with RVR and non-RVR-A.  The eﬀectiveness of 
extending treatment duration could not be fully evalu-
ated for these patients because only 16 patients with 
non-RVR-B received extended therapy in the present 
study; hence,  the SVR rate of 44ｵ (7/16) with 
extended therapy could not be eﬀectively compared to 
the SVR rate of non-RVR-B patients with standard 
therapy (51ｵ,  18/35).
　 In conclusion,  extending treatment duration might 
improve the therapeutic outcomes of non-RVR patients 
with undetectable HCV RNA at week 8 of treatment 
and insuﬃcient drug adherence to PegIFN or RBV 
during treatment.  This ﬁnding might be useful in 
creating a guideline for extending treatment duration 
in antiviral therapy for patients with CHC genotype 
2.
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